JP2025506206A5 - - Google Patents
Info
- Publication number
- JP2025506206A5 JP2025506206A5 JP2024547861A JP2024547861A JP2025506206A5 JP 2025506206 A5 JP2025506206 A5 JP 2025506206A5 JP 2024547861 A JP2024547861 A JP 2024547861A JP 2024547861 A JP2024547861 A JP 2024547861A JP 2025506206 A5 JP2025506206 A5 JP 2025506206A5
- Authority
- JP
- Japan
- Prior art keywords
- ring
- cancer
- compound according
- compound
- cycloalkyl group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263310400P | 2022-02-15 | 2022-02-15 | |
| US63/310,400 | 2022-02-15 | ||
| US202263341238P | 2022-05-12 | 2022-05-12 | |
| US63/341,238 | 2022-05-12 | ||
| PCT/US2023/013118 WO2023158679A2 (en) | 2022-02-15 | 2023-02-15 | Thiostrepton-inspired compounds for treatment of cancer and preparation thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025506206A JP2025506206A (ja) | 2025-03-07 |
| JP2025506206A5 true JP2025506206A5 (enExample) | 2026-02-19 |
Family
ID=87579015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024547861A Pending JP2025506206A (ja) | 2022-02-15 | 2023-02-15 | がん治療のためのチオストレプトンから着想された化合物及びその調製 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250144078A1 (enExample) |
| EP (1) | EP4479390A4 (enExample) |
| JP (1) | JP2025506206A (enExample) |
| CN (1) | CN119301105A (enExample) |
| AU (1) | AU2023222756A1 (enExample) |
| CA (1) | CA3252219A1 (enExample) |
| TW (1) | TW202342492A (enExample) |
| WO (1) | WO2023158679A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024044744A2 (en) * | 2022-08-26 | 2024-02-29 | Wake Forest University Health Sciences | Peroxiredoxin 3 inhibitors and methods of use for treating cancer |
| US20260109695A1 (en) * | 2022-08-26 | 2026-04-23 | Wake Forest University Health Sciences | Peroxiredoxin 3 inhibitors and methods of use for treating cancer |
| WO2024044748A2 (en) * | 2022-08-26 | 2024-02-29 | Wake Forest University Health Sciences | Peroxiredoxin 3 inhibitors and methods of use for treating cancer |
| EP4665373A2 (en) * | 2023-02-15 | 2025-12-24 | RS Oncology, LLC | Select thiostrepton-inspired compounds for treatment of cancer and preparation thereof |
| WO2025265000A1 (en) * | 2024-06-21 | 2025-12-26 | Rs Oncology, Llc | Modified thiostrepton-inspired compounds for treatment of cancer and preparation thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017095751A1 (en) * | 2015-12-02 | 2017-06-08 | Partikula Llc | Compositions and methods for modulating cancer cell metabolism |
| EP3685846A1 (en) * | 2019-01-24 | 2020-07-29 | Genethon | Use of thiostrepton or its derivatives for the treatment of genetic diseases linked to a protein conformational disorder |
-
2023
- 2023-02-15 CA CA3252219A patent/CA3252219A1/en active Pending
- 2023-02-15 AU AU2023222756A patent/AU2023222756A1/en active Pending
- 2023-02-15 CN CN202380027720.4A patent/CN119301105A/zh active Pending
- 2023-02-15 WO PCT/US2023/013118 patent/WO2023158679A2/en not_active Ceased
- 2023-02-15 JP JP2024547861A patent/JP2025506206A/ja active Pending
- 2023-02-15 TW TW112105454A patent/TW202342492A/zh unknown
- 2023-02-15 EP EP23756836.5A patent/EP4479390A4/en active Pending
- 2023-02-15 US US18/837,725 patent/US20250144078A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025506206A5 (enExample) | ||
| JP2007511504A5 (enExample) | ||
| JP2025160318A5 (enExample) | ||
| JP2024534840A5 (enExample) | ||
| JP2006511534A5 (enExample) | ||
| JP2019516700A5 (enExample) | ||
| JP2023126440A5 (enExample) | ||
| JP2005504039A5 (enExample) | ||
| JP2007535520A (ja) | 抗腫瘍作用を有するインドール及びアザインドール誘導体 | |
| JP2011524422A5 (enExample) | ||
| JP2020517616A5 (enExample) | ||
| JP2010510215A5 (enExample) | ||
| JP2013510860A5 (enExample) | ||
| JP2018516238A5 (enExample) | ||
| JP2018519245A5 (enExample) | ||
| JP2017538677A5 (enExample) | ||
| JP2020063289A5 (enExample) | ||
| FR2928151A1 (fr) | Derives platine-carbene n-heterocyclique, leur preparation et leur application en therapeutique | |
| JP2022526220A5 (enExample) | ||
| JP2025118609A (ja) | Ｎｕｒｒ１受容体調節因子 | |
| JP2010518158A5 (enExample) | ||
| KR101129088B1 (ko) | Ｎ-［6-(시스-2,6-디메틸모르폴린-4-일)피리딘-3-일］-2-메틸-4'-(트리플루오로메톡시)［1,1'-비페닐］-3-카르복스아미드의 염 | |
| JP2009529028A (ja) | ルテニウム（ｉｉ）化合物 | |
| JP2019504833A5 (enExample) | ||
| JP2005511594A5 (enExample) |